哈尔滨医科大学学报
哈爾濱醫科大學學報
합이빈의과대학학보
JOURNAL OF HARBIN MEDICAL UNIVERSITY
2013年
5期
418-421
,共4页
田国梅%康正%付鹏%朱华%赵长久
田國梅%康正%付鵬%硃華%趙長久
전국매%강정%부붕%주화%조장구
乳腺癌细胞MCF-7%药物敏感性%反义寡核苷酸%MDM2基因%紫杉醇
乳腺癌細胞MCF-7%藥物敏感性%反義寡覈苷痠%MDM2基因%紫杉醇
유선암세포MCF-7%약물민감성%반의과핵감산%MDM2기인%자삼순
breast cancer cells MCF-7%chemosensitivity%antisense oligonucleotide%MDM2 gene%paclitaxel
目的:探讨靶向MDM2基因的反义寡核苷酸( ASON)对MCF-7细胞株乳腺癌紫杉醇药物敏感性的影响。方法人工合成一段针对MDM2 mRNA的反义寡核苷酸及错义寡核苷酸,采用脂质体介导MDM2 ASON转染MCF-7乳腺癌细胞系,RT-PCR和Western blot方法检测其抑制效率,MTT观察细胞给药后的增殖能力。结果 MDM2 ASON转染细胞,给予紫杉醇处理后,MDM2 mRNA和蛋白表达下调,其中A500下调最显著,细胞增殖抑制率明显增高,其中A500抑制率高达(13.0±0.84)%。结论 ASON转染细胞后,下调MDM2的表达,促进凋亡,提高了对紫杉醇的敏感性,为乳腺癌治疗提供了新疗法。
目的:探討靶嚮MDM2基因的反義寡覈苷痠( ASON)對MCF-7細胞株乳腺癌紫杉醇藥物敏感性的影響。方法人工閤成一段針對MDM2 mRNA的反義寡覈苷痠及錯義寡覈苷痠,採用脂質體介導MDM2 ASON轉染MCF-7乳腺癌細胞繫,RT-PCR和Western blot方法檢測其抑製效率,MTT觀察細胞給藥後的增殖能力。結果 MDM2 ASON轉染細胞,給予紫杉醇處理後,MDM2 mRNA和蛋白錶達下調,其中A500下調最顯著,細胞增殖抑製率明顯增高,其中A500抑製率高達(13.0±0.84)%。結論 ASON轉染細胞後,下調MDM2的錶達,促進凋亡,提高瞭對紫杉醇的敏感性,為乳腺癌治療提供瞭新療法。
목적:탐토파향MDM2기인적반의과핵감산( ASON)대MCF-7세포주유선암자삼순약물민감성적영향。방법인공합성일단침대MDM2 mRNA적반의과핵감산급착의과핵감산,채용지질체개도MDM2 ASON전염MCF-7유선암세포계,RT-PCR화Western blot방법검측기억제효솔,MTT관찰세포급약후적증식능력。결과 MDM2 ASON전염세포,급여자삼순처리후,MDM2 mRNA화단백표체하조,기중A500하조최현저,세포증식억제솔명현증고,기중A500억제솔고체(13.0±0.84)%。결론 ASON전염세포후,하조MDM2적표체,촉진조망,제고료대자삼순적민감성,위유선암치료제공료신요법。
Objective To investigate the effects of the MDM2 antisense oligonucleotide ( ASON) on chemosensitivity to paclitaxel in human breast cancer cells MCF-7.Methods ASON and missense oligonucleotides were synthesized , MCF-7 cell lines was transfected by li-posome-mediated ASON , the inhibition efficiency was detected by RT-PCR and Western blot , proliferation of cells was observed by MTT .Results ASON transfected MDM2 mRNA and pro-tein expressions were significantly reduced after paclitaxel treatment , A500 was the most signif-icant, proliferation inhibition rate was significantly higher , and A500 inhibition rate was (13.0 ±0.84 )%.Conclusion ASON effectively suppresses the expression of MDM 2 mRNA, in-creases apoptosis and enhances the chemosensitivity to paclitaxel in MCF-7 , which provides a new treatment for breast cancer therapy .